Table 1.

Demografic data and I‐AChE treatment

Treatment	Patient	Tideglusib administration	Age (y)	Gender	AChE‐I treatment	AChE‐I treatment duration (y)
Placebo	1		72	M	Donepezil	2.0
	2		80	M	Donepezil	5.0
	3		83	M	Rivastigmine	0.8
	4		61	F	Donepezil	2.0
	5		78	F	Galantamine	2.0
Tideglusib	6	QOD	64	M	Galantamine	1.1
	7	QOD	59	F	Rivastigmine	1.0
	8	QD	68	F	Galantamine	3.2
	9	QOD	78	M	Rivastigmine	0.4
	10	QD	66	M	Donepezil	3.4
	11	QOD	71	M	Rivastigmine	1.3
	12	QOD	63	M	Rivastigmine	0.5
	13	QD	81	M	Rivastigmine	1.9
	14	QD	73	M	Galantamine	0.9
	15	QD	68	M	Rivastigmine	1.1
	16	QOD	76	M	Donepezil	1.8
	17	QD	68	F	Donepezil	2.4
	18	QD	65	F	Donepezil	4.81
	19	QOD	77	M	Donepezil	1.93

AD patients were administered with placebo or 1,000 mg of tideglusib orally using two different regimes: once a day (QD) and every other day (QOD).

F/M, female/male. All AD patients were under AChE inhibitor (AChE‐I) treatment for at least 4 months prior to the enrollment into the trial. AChE‐I tratmen duration (years, Y) is indicated.